 Artist: H-Blockx: mp3 download Genre(s): Alternative Metal ROck: Alternative Alternative Metal ROck: Alternative Discography:  No Excuses Year: 2004 Tracks: 13  More Than A Decade: Best Of Year: 2004 Tracks: 19  Get In The Ring Year: 2002 Tracks: 12  Fly Eyes Year: 1998 Tracks: 15  Discover My Soul Year: 1996 Tracks: 14  Time To Move Year: 1994 Tracks: 13 Formed in Münster, Germany in 1991, H-Blockx was a punk-tinged alternative metal band named after Irish put one over for high-security prison house cells. The band's initial card featured singer/rapper Henning "MC-H" Wehland, guitar player Tim Tenambergen, bassist Stefan "Gudze" Hinz, and drummer Johann-Christoph "Mason" Maass; singer/rapper David Gappa was added in 1992. The German pronounce Sing Sing issued their debut record album, Clock fourth dimension to Move, in 1994, which became something of a shoot in German-speaking Europe. Follow-up Discover My Soul appeared in 1996, consolidating their popularity; the undermentioned yr, Maass was laid-off from the chemical group and replaced by Marco Minneman. In 1998, the grouping released its third album, Fly Eyes, which became their official U.S. debut the undermentioned yr. 1999 too saw the chemical group recording new songs for the soundtrack of the German film Sleep with Boom Bang, as well as replacing Minneman with Steffen Wilking. |
Thursday, 28 August 2008
Download H-Blockx mp3
Monday, 18 August 2008
Bavarian Nordic Announces Partnership With National Cancer Institute In The US And Obtains Rights To A New Vaccine Candidate
�Bavarian Nordic's US subsidiary company, BN ImmunoTherapeutics has entered into a scientific partnership with the National Cancer Institute (NCI) in the United States. Under the Cooperative Research and Development Agreement (CRADA) the NCI and Bavarian Nordic testament jointly develop new immunotherapies for the treatment of prostate malignant neoplastic disease. Under the CRADA, BN ImmunoTherapeutics has rights to exclusively licence intellectual belongings that results from this collaboration.
Bavarian Nordic will in the future explore opportunities for extending this collaboration to further rise its cancer the Crab projects. By combining Bavarian Nordic's expertise within genus Cancer vaccine exploitation with one of the world's leading centres of excellence within cancer research, the company is confident that this collaboration volition result in new and innovative solutions to a disease area with high school unmet medical needs as well as expand and accelerate Bavarian Nordic's malignant neoplastic disease activities.
Through the collaboration and a license agreement with the United States Public Health Service, the company has obtained rights to noetic property rights covering a prostate cancer vaccine product candidate in late form II clinical development. Data from key clinical studies with this vaccine nominee are currently being evaluated. Later in 2008 the company testament inform the market about how this development project will give birth a future in the pipeline of Bavarian Nordic.
About the NCI
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH) and is the United States federal government's leading cancer research organization.
- The National Cancer Institute (NCI) has played an active role in the development of drugs for cancer treatment for over 50 years. This is reflected in the fact that approximately one half of the chemotherapeutic drugs currently used by oncologists for cancer treatment were discovered and/or developed at NCI.
- NCI has supported the research efforts of at least 20 Nobel Prize winners. For approximately half of these Nobel laureates, NCI supported the awarded research.
- According to a 1996 NCI analysis of drugs approved by the FDA, two-thirds of the antitumour drugs approved as of the end of 1995 were NCI-sponsored Investigational New Drugs.
The collaboration with the NCI does not change Bavarian Nordic's previously announced fiscal guidance for 2008.
Anders Hedegaard, President & CEO of Bavarian Nordic, commented:
"I am very happy to see that we are consolidating our inviolable relationships within the US. The NCI relationship opens up for us new and exciting opportunities inside the field of cancer and we are proud to bring together forces with one of the nearly prestigious and well-established cancer research organisations in the world. In the collaboration with NCI Bavarian Nordic benefits from the enormous expertise in cancer therapeutics development that is present in the NCI organization. This will truly fortify cancer as a strategical focus country in days to come, in pipeline with our outlined strategy."
About Bavarian Nordic
Bavarian Nordic A/S is a leading industrial biotechnology company development and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focussed in triad areas: biological defence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented applied science MVA-BN� is one of the world's safest, multi-valued vaccine vectors. Bavarian Nordic has on-going contracts with the US government for the late-stage development and procurement of the company's third-generation variola vaccine, IMVAMUNE�.
Bavarian Nordic is listed on the OMX Nordic Exchange Copenhagen under the symbolisation BAVA.
Bavarian Nordic
More information
Bavarian Nordic will in the future explore opportunities for extending this collaboration to further rise its cancer the Crab projects. By combining Bavarian Nordic's expertise within genus Cancer vaccine exploitation with one of the world's leading centres of excellence within cancer research, the company is confident that this collaboration volition result in new and innovative solutions to a disease area with high school unmet medical needs as well as expand and accelerate Bavarian Nordic's malignant neoplastic disease activities.
Through the collaboration and a license agreement with the United States Public Health Service, the company has obtained rights to noetic property rights covering a prostate cancer vaccine product candidate in late form II clinical development. Data from key clinical studies with this vaccine nominee are currently being evaluated. Later in 2008 the company testament inform the market about how this development project will give birth a future in the pipeline of Bavarian Nordic.
About the NCI
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH) and is the United States federal government's leading cancer research organization.
- The National Cancer Institute (NCI) has played an active role in the development of drugs for cancer treatment for over 50 years. This is reflected in the fact that approximately one half of the chemotherapeutic drugs currently used by oncologists for cancer treatment were discovered and/or developed at NCI.
- NCI has supported the research efforts of at least 20 Nobel Prize winners. For approximately half of these Nobel laureates, NCI supported the awarded research.
- According to a 1996 NCI analysis of drugs approved by the FDA, two-thirds of the antitumour drugs approved as of the end of 1995 were NCI-sponsored Investigational New Drugs.
The collaboration with the NCI does not change Bavarian Nordic's previously announced fiscal guidance for 2008.
Anders Hedegaard, President & CEO of Bavarian Nordic, commented:
"I am very happy to see that we are consolidating our inviolable relationships within the US. The NCI relationship opens up for us new and exciting opportunities inside the field of cancer and we are proud to bring together forces with one of the nearly prestigious and well-established cancer research organisations in the world. In the collaboration with NCI Bavarian Nordic benefits from the enormous expertise in cancer therapeutics development that is present in the NCI organization. This will truly fortify cancer as a strategical focus country in days to come, in pipeline with our outlined strategy."
About Bavarian Nordic
Bavarian Nordic A/S is a leading industrial biotechnology company development and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focussed in triad areas: biological defence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented applied science MVA-BN� is one of the world's safest, multi-valued vaccine vectors. Bavarian Nordic has on-going contracts with the US government for the late-stage development and procurement of the company's third-generation variola vaccine, IMVAMUNE�.
Bavarian Nordic is listed on the OMX Nordic Exchange Copenhagen under the symbolisation BAVA.
Bavarian Nordic
More information
Saturday, 9 August 2008
Jessamine
Artist: Jessamine
Genre(s):
Indie
Discography:
Long Arm Of Coincidence
Year: 1996
Tracks: 10
Jessamine
Year: 1995
Tracks: 10
Drone-rockers Jessamine formed in the college townsfolk of Galion, Ohio before relocating to Seattle, where they earned batting order for "Your Head Is So Small..., " a 1994 single on the Sub Pop label. After signing to Kranky, Jessamine -- vocalist/guitarist Rex Ritter, bassist/vocalist Dawn Smithson, keyboardist Andy Brown and drummer Michael Faeth -- issued their self-titled debut in 1995; their review, The Long Arm of Coincidence, was released a year subsequently. A Pox on You, a coaction with Spectrum, followed, as did the singles compendium Another Fictionalized History; their one-third studio LP, Don't Stay Too Long, appeared in 1998. Just subsequently the spillage of Living Sound, an archival resilient outing recorded with Experimental Audio Research ringleader Sonic Boom, Jessamine disbanded.
Subscribe to:
Posts (Atom)